G-III Apparel (GIII) Beats Consensus
Post# of 54
For its first quarter fiscal 2016, GIII posted net sales of $433.0 million, an 18% increase year over year, and net income of $6.8 million, or $0.15 per diluted share, compared to net income of $1.3 million, or $0.03 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.07 earnings per share on revenues of $405.76 million for the period.
The company has raised its guidance for the full year fiscal 2016. GIII now expects net sales of approximately $2.40 billion and net income to be in a range of $2.66 to $2.76 per diluted share, compared to its previous guidance of net sales of approximately $2.37 billion and net income between $2.53 and $2.63 per diluted share
GIII designs, manufactures, and markets women's and men's apparel. Its products include outerwear, dresses, sportswear, swimwear, women's suits, and women's performance wear.
More about G-III Apparel Group, Ltd. (GIII) at www.g-iii.com
**
After the closing bell on Tuesday, Ambarella, Inc. (AMBA) reported stronger-than-expected quarterly financial results.
For its first quarter fiscal 2016, AMBA posted revenue of $71.0 million, a 73.5% increase year over year, and non-GAAP net income of $23.7 million, or $0.71 per diluted ordinary share, compared to non-GAAP net income of $7.8 million, or $0.25 per diluted ordinary share in the same quarter the prior year, exceeding the Capital IQ Consensus Estimate of $0.58 earnings per share on revenues of $67.1 million for the period
AMBA said that in addition to continued growth from its existing wearable, IP security and automotive video recorder camera markets, the company sees increased activity across a wide range of home monitoring cameras including models by U.S. service providers, as well as from quadcopters or flying cameras.
AMBA is a leading developer of low-power, high-definition (HD) and Ultra HD video compression and image processing solutions.
More about Ambarella, Inc. (AMBA) at www.ambarella.com
**
On May 29, June 1 and June 2, 2015, Kevin C. Tang, Chairman of Heron Therapeutics, Inc. (HRTX) purchased a total of 150,000 shares of the company in a price range of $19.30 to $23.84, according to a regulatory filing ( FORM 4 ) with the Securities and Exchange Commission (SEC).
Last week, HRTX reported positive, top-line results from its recently completed Phase 3 MAGIC study evaluating the efficacy and safety of its 5-HT3 receptor antagonist product candidate SUSTOL (granisetron injection, extended release), as part of a three-drug regimen for the prevention of delayed-onset chemotherapy-induced nausea and vomiting following administration of highly emetogenic chemotherapy agents.
HRTX is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs.
More about Heron Therapeutics, Inc. (HRTX) at www.herontx.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE PR Network, which disseminates community, state, national and global news & information and is also the portal in promoting the company's services, such as its business directory, business-to-business global trading, real estate, press release and video distribution, discounted vouchers and advertising platforms
CRWE's growing network of community targeted sites is expected to be a one-stop shop for the various needs of consumers.
Curbiz ( www.curbiz.com ), in development stage, is an online business directory connecting people with local, state, country and global businesses. Curbiz will provide local advertising services, including free and paid business listing services to businesses of various sizes, as well as enable businesses to deliver targeted search advertising to large local audiences through its Website network and partnership with CRWE PR.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer